| 000 | 01186 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250512052726.0 | ||
| 264 | 0 | _c19880303 | |
| 008 | 198803s 0 0 eng d | ||
| 022 | _a0014-3022 | ||
| 024 | 7 |
_a10.1159/000116207 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLees, A J | |
| 245 | 0 | 0 |
_aA sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. _h[electronic resource] |
| 260 |
_bEuropean neurology _c1987 |
||
| 300 |
_a126-34 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aBenserazide _xpharmacokinetics |
| 650 | 0 | 4 | _aCircadian Rhythm |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 |
_aDrug Combinations _xpharmacokinetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrazines _xtherapeutic use |
| 650 | 0 | 4 |
_aLevodopa _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMovement Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aParkinson Disease _xcomplications |
| 773 | 0 |
_tEuropean neurology _gvol. 27 Suppl 1 _gp. 126-34 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000116207 _zAvailable from publisher's website |
| 999 |
_c3434039 _d3434039 |
||